WO2008099615A1 - 微粒子油性懸濁液を含む医薬組成物 - Google Patents

微粒子油性懸濁液を含む医薬組成物 Download PDF

Info

Publication number
WO2008099615A1
WO2008099615A1 PCT/JP2008/000230 JP2008000230W WO2008099615A1 WO 2008099615 A1 WO2008099615 A1 WO 2008099615A1 JP 2008000230 W JP2008000230 W JP 2008000230W WO 2008099615 A1 WO2008099615 A1 WO 2008099615A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition containing
fine particle
containing fine
based suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/000230
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Yasunori Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Priority to EP08710384.2A priority Critical patent/EP2123255B1/en
Priority to US12/526,825 priority patent/US8309138B2/en
Priority to KR1020097019114A priority patent/KR101434706B1/ko
Priority to ES08710384T priority patent/ES2423929T3/es
Priority to CA2677842A priority patent/CA2677842C/en
Priority to JP2008558013A priority patent/JP4588791B2/ja
Priority to AU2008215659A priority patent/AU2008215659B2/en
Publication of WO2008099615A1 publication Critical patent/WO2008099615A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/JP2008/000230 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物 Ceased WO2008099615A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP08710384.2A EP2123255B1 (en) 2007-02-16 2008-02-15 Pharmaceutical composition containing fine particle oil-based suspension
US12/526,825 US8309138B2 (en) 2007-02-16 2008-02-15 Pharmaceutical composition comprising microparticle oily suspension
KR1020097019114A KR101434706B1 (ko) 2007-02-16 2008-02-15 미립자 유성 현탁액을 포함하는 의약 조성물
ES08710384T ES2423929T3 (es) 2007-02-16 2008-02-15 Composición farmacéutica que contiene suspensión basada en aceite de partículas finas
CA2677842A CA2677842C (en) 2007-02-16 2008-02-15 Pharmaceutical composition comprising microparticle oily suspension
JP2008558013A JP4588791B2 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物
AU2008215659A AU2008215659B2 (en) 2007-02-16 2008-02-15 Pharmaceutical composition comprising microparticle oily suspension

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-035916 2007-02-16
JP2007035916 2007-02-16

Publications (1)

Publication Number Publication Date
WO2008099615A1 true WO2008099615A1 (ja) 2008-08-21

Family

ID=39689861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000230 Ceased WO2008099615A1 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物

Country Status (9)

Country Link
US (1) US8309138B2 (https=)
EP (1) EP2123255B1 (https=)
JP (2) JP4588791B2 (https=)
KR (1) KR101434706B1 (https=)
CN (1) CN101610754A (https=)
AU (1) AU2008215659B2 (https=)
CA (1) CA2677842C (https=)
ES (1) ES2423929T3 (https=)
WO (1) WO2008099615A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
CN103655512B (zh) * 2013-12-12 2015-05-20 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
WO2019022152A1 (ja) 2017-07-26 2019-01-31 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
EP3668957A4 (en) * 2017-08-17 2021-06-02 University of Delaware Furan based compositions and methods of making thereof
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014081A1 (en) 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
WO1996025405A1 (en) 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
WO1998052940A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP2000086657A (ja) 1998-09-10 2000-03-28 Teikoku Hormone Mfg Co Ltd ５−アミノイソキサゾール誘導体
WO2000039116A1 (en) 1998-12-25 2000-07-06 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
WO2000064894A1 (en) 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
JP2000516244A (ja) 1996-08-22 2000-12-05 リサーチ・トライアングル・ファーマシューティカルズ 水不溶性物質の微粒子を含む組成物およびその製造方法
WO2002024172A1 (en) * 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
JP2002528492A (ja) 1998-10-30 2002-09-03 エフ．ホフマン−ラ ロシュ アーゲー 小粒径を有するイソトレチノイン組成物および製造方法
JP2002533378A (ja) * 1998-12-23 2002-10-08 アムジエン・インコーポレーテツド タンパク質の徐放用ポリオール／油懸濁液
WO2004000846A1 (en) 2002-06-20 2003-12-31 Celltech R & D Limited Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
WO2004014907A1 (en) 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
WO2004017965A1 (en) 2002-08-23 2004-03-04 Ionix Pharmaceuticals Limited 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2004022555A1 (en) 2002-09-06 2004-03-18 Vertex Pharmaceuticals Incorporated Isoxazoles and their use in the treatment of ischemic diseases
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
JP2004520269A (ja) * 2000-08-24 2004-07-08 シュバルツ　ファルマ　アクチェンゲゼルシャフト Ｎ−０９２３を投与するための新規の医薬組成物
WO2004072072A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
WO2004073628A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
WO2004073692A1 (ja) 2003-02-18 2004-09-02 Yamashita, Shinji 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
JP2005112753A (ja) 2003-10-06 2005-04-28 Sankyo:Kk 生物学的利用能を向上させたソフトカプセル
JP2005516943A (ja) 2001-12-20 2005-06-09 ファルマシア コーポレーション 経口投与に適した医薬品懸濁液
WO2005073189A1 (en) 2004-01-30 2005-08-11 Smithkline Beecham Corporation Fused heteroyral derivatives for use as p38 kinase inhibitors
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
WO2005105052A1 (en) * 2004-05-04 2005-11-10 Hormos Medical Ltd. Novel oral formulations of ospemifene
JP2006513267A (ja) 2002-12-18 2006-04-20 アルゴルクス ファーマスーティカルズ，インク カプサイシノイドの投与
WO2006070927A1 (ja) 2004-12-28 2006-07-06 Aska Pharmaceutical Co., Ltd. ピリミジニルイソオキサゾール誘導体
JP2007039408A (ja) 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0548238A1 (en) 1990-09-13 1993-06-30 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
US5651983A (en) 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
CA2320087C (en) 1998-02-09 2006-12-19 Joel Bolonick Treatment of chronic inflammatory disorders of the gastrointestinal tract
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
EA004683B1 (ru) 1999-02-23 2004-06-24 Мерк Энд Ко., Инк. Фармацевтическая композиция, содержащая омепразол
CA2386277A1 (en) 1999-10-01 2001-04-12 Natco Pharma Limited An improved pharmaceutical composition and a process for its preparation
IN192188B (https=) 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
DE60319073T2 (de) 2002-03-20 2009-02-05 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
WO2005013938A1 (ja) 2003-08-06 2005-02-17 Eisai Co., Ltd. 薬物超微粒子の製造法及び製造装置
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014081A1 (en) 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
WO1996025405A1 (en) 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
JP2000516244A (ja) 1996-08-22 2000-12-05 リサーチ・トライアングル・ファーマシューティカルズ 水不溶性物質の微粒子を含む組成物およびその製造方法
WO1998052940A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP2000086657A (ja) 1998-09-10 2000-03-28 Teikoku Hormone Mfg Co Ltd ５−アミノイソキサゾール誘導体
JP2002528492A (ja) 1998-10-30 2002-09-03 エフ．ホフマン−ラ ロシュ アーゲー 小粒径を有するイソトレチノイン組成物および製造方法
JP2002533378A (ja) * 1998-12-23 2002-10-08 アムジエン・インコーポレーテツド タンパク質の徐放用ポリオール／油懸濁液
WO2000039116A1 (en) 1998-12-25 2000-07-06 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
WO2000064894A1 (en) 1999-04-23 2000-11-02 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
JP2004520269A (ja) * 2000-08-24 2004-07-08 シュバルツ　ファルマ　アクチェンゲゼルシャフト Ｎ−０９２３を投与するための新規の医薬組成物
WO2002024172A1 (en) * 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
JP2005516943A (ja) 2001-12-20 2005-06-09 ファルマシア コーポレーション 経口投与に適した医薬品懸濁液
WO2004000846A1 (en) 2002-06-20 2003-12-31 Celltech R & D Limited Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
WO2004014907A1 (en) 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
WO2004017965A1 (en) 2002-08-23 2004-03-04 Ionix Pharmaceuticals Limited 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
WO2004022555A1 (en) 2002-09-06 2004-03-18 Vertex Pharmaceuticals Incorporated Isoxazoles and their use in the treatment of ischemic diseases
JP2006513267A (ja) 2002-12-18 2006-04-20 アルゴルクス ファーマスーティカルズ，インク カプサイシノイドの投与
WO2004072072A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
WO2004073628A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
WO2004073692A1 (ja) 2003-02-18 2004-09-02 Yamashita, Shinji 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
JP2005112753A (ja) 2003-10-06 2005-04-28 Sankyo:Kk 生物学的利用能を向上させたソフトカプセル
WO2005073189A1 (en) 2004-01-30 2005-08-11 Smithkline Beecham Corporation Fused heteroyral derivatives for use as p38 kinase inhibitors
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
WO2005105052A1 (en) * 2004-05-04 2005-11-10 Hormos Medical Ltd. Novel oral formulations of ospemifene
WO2006070927A1 (ja) 2004-12-28 2006-07-06 Aska Pharmaceutical Co., Ltd. ピリミジニルイソオキサゾール誘導体
JP2007039408A (ja) 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 5, no. 1, 1997, pages 49 - 64
CLIN. TRANSPLANTATION, vol. 10, 1996, pages 364 - 373
GUT., vol. 40, 1997, pages 628 - 633
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 41, 1988, pages 245 - 254
J. PHARMACOL. EXP. THER., vol. 284, 1998, pages 687 - 692
N. ENGL. J. MED., vol. 337, 1997, pages 1029 - 1035
PHARMACEUTICAL RESEARCH, vol. 18, no. 6, 2001, pages 788 - 793
See also references of EP2123255A4 *
YAMAMOTO H. ET AL.: "Ryushi Bussei Seigyo ni yoru Biryushi Drug Delivery System no Kino Sekkei", DRUG DELIVERY SYSTEM, vol. 17, no. 4, 2002, pages 321 - 329, XP008112377 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4

Also Published As

Publication number Publication date
US8309138B2 (en) 2012-11-13
CA2677842A1 (en) 2008-08-21
CN101610754A (zh) 2009-12-23
JP4588791B2 (ja) 2010-12-01
KR101434706B1 (ko) 2014-08-26
EP2123255A1 (en) 2009-11-25
US20100092565A1 (en) 2010-04-15
JPWO2008099615A1 (ja) 2010-05-27
CA2677842C (en) 2014-09-16
KR20090117894A (ko) 2009-11-13
ES2423929T3 (es) 2013-09-25
EP2123255B1 (en) 2013-05-15
EP2123255A4 (en) 2010-06-02
AU2008215659A1 (en) 2008-08-21
JP2010120974A (ja) 2010-06-03
AU2008215659B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
WO2008099615A1 (ja) 微粒子油性懸濁液を含む医薬組成物
WO2003084518A3 (fr) Suspension orale de microcapsules de principes actifs
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
WO2007062266A3 (en) Ganaxolone formulations and methods for the making and use thereof
WO2007123955A3 (en) Stable hydroalcoholic oral spray formulations and methods
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
WO2008149788A1 (ja) 固形透析用剤
WO2010002613A3 (en) Method of making a dry powder pharmaceutical composition
WO2003084517A3 (fr) Suspension orale de microcapsules d’amoxicilline
WO2006099514A3 (en) Drug delivery compositions and related methods
WO2006121870A3 (en) Silicon nanosponge particles
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2008084854A1 (ja) セルロース微粒子並びにその分散液及び分散体
WO2007033372A3 (en) Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2008106503A3 (en) Discrete size and shape specific pharmaceutical organic nanoparticles
WO2009122301A3 (en) Rasagiline mesylate particles and process for the preparation thereof
WO2007072992A3 (en) Solid preparation containing an insulin sensitizer
TW200505485A (en) Sustained drug-release particles and process for producing the same
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
EA200701107A1 (ru) Твердая фармацевтическая композиция, содержащая валсартан
EA201070378A1 (ru) Фармацевтические составы орлистата
WO2008025524A3 (de) Aerosolzubereitung umfassend peloide
WO2006068890A3 (en) Lipid particles comprising bioactive agents, methods of preparing and uses thereof
WO2008143239A1 (ja) 結晶性微粉化粒子
WO2007075381A3 (en) Pharmaceutical compositions of ilaprazole

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880005121.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710384

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008558013

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2677842

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008215659

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008215659

Country of ref document: AU

Date of ref document: 20080215

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008710384

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097019114

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12526825

Country of ref document: US